Molecular pharmacology is the mechanistic foundation of drug discovery. Understanding not just whether a compound is potent, but precisely how it interacts with its target — the kinetics, the mechanism, the pathway consequences — determines whether a candidate will succeed in the clinic. AstraNova's molecular pharmacology team delivers that depth through validated, multiparametric assay systems.
Send us the target class and compound context. We will map a mechanistic pharmacology plan that clarifies potency, kinetics, pathway response, and selectivity.
Comprehensive characterization of compound interactions with receptor targets including binding kinetics, equilibrium binding constants, functional agonism/antagonism, and allosteric modulation using radioligand binding, HTRF, and label-free technologies.
High-precision enzyme assay platforms characterizing substrate kinetics, inhibitor mechanisms, and covalent binding events. Our biochemical pharmacology team provides the mechanistic depth that separates clinical-quality packages from simple IC50 measurements.
Bridging biochemical potency and cellular activity requires robust intracellular target engagement technologies. AstraNova offers validated CETSA, NanoBRET, and proximity ligation platforms to confirm on-target pharmacology in intact cells.
Multi-pathway signaling characterization enables full mechanistic understanding of compound pharmacology. Our team profiles downstream pathway activation, signaling bias, and cross-pathway effects for complete pharmacological characterization.
Bring us the program question, constraints, and next decision point. We will map the right assays, controls, timeline, and reporting package before the first plate is run.
